Growth and the growth hormone-insulin like growth factor 1 axis in children with chronic inflammation: Current Evidence, Gaps in Knowledge, and Future Directions

Endocrine Reviews

Volumn 37, Issue 1, 2016, Pages 62-110

  Wong, S C ^a   Dobie, R ^b   Altowati, M A ^a   Werther, G A ^c   Farquharson, C ^b   Ahmed, S F ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GLUCOCORTICOID; GROWTH FACTOR; GROWTH HORMONE; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C; GROWTH PROMOTOR; HUMAN GROWTH HORMONE; IGF1 PROTEIN, HUMAN; RECOMBINANT PROTEIN;

CATCH UP GROWTH; CHILD GROWTH; CHILD NUTRITION; CHONDROGENESIS; CHRONIC DISEASE; CHRONIC INFLAMMATION; CYSTIC FIBROSIS; DELAYED PUBERTY; GROWTH DISORDER; GROWTH PLATE; HUMAN; INFLAMMATORY BOWEL DISEASE; JUVENILE RHEUMATOID ARTHRITIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ADOLESCENT; ANIMAL; ARTHRITIS, JUVENILE; CHILD; COMBINATION DRUG THERAPY; DRUG EFFECTS; EPIPHYSIS PLATE; EVIDENCE BASED MEDICINE; GENETICS; GROWTH DISORDERS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PUBERTY, DELAYED;

ADOLESCENT; ANIMALS; ARTHRITIS, JUVENILE; CHILD; COMBINED MODALITY THERAPY; CYSTIC FIBROSIS; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; GROWTH DISORDERS; GROWTH PLATE; GROWTH SUBSTANCES; HUMAN GROWTH HORMONE; HUMANS; INFLAMMATORY BOWEL DISEASES; INSULIN-LIKE GROWTH FACTOR I; PRACTICE GUIDELINES AS TOPIC; PUBERTY, DELAYED; RECOMBINANT PROTEINS;

EID: 84957831200     PISSN: None     EISSN: 0163769X     Source Type: Journal    
DOI: 10.1210/er.2015-1026     Document Type: Review

References (477)

1. Bechtold S, Roth J. Natural history of growth and body composition in juvenile idiopathic arthritis. Horm Res. 2009;72(suppl 1):13-19.
2. Griffiths AM. Growth retardation in early-onset inflammatory bowel disease: should we monitor and treat these patients differently? Dig Dis. 2009;27:404-411.
3. GriffithsAM, Nguyen P, Smith C, MacMillan JH, Sherman PM. Growth and clinical course of children with Crohn's disease. Gut. 1993;34:939-943.
4. Zhang Z, Lindstrom MJ, Lai HJ. Pubertal height velocity and associations with prepubertal and adult heights in cystic fibrosis. J Pediatr. 2013;163:376-382.
5. Umlawska W, Susanne C. Growth and nutritional status in children and adolescents with cystic fibrosis. Ann Hum Biol. 2008;35:145-153.
6. Mason A, Malik S, Russell RK, Bishop J, McGrogan P, Ahmed SF. Impact of inflammatory bowel disease on pubertal growth. Horm Res Paediatr. 2011;76:293-299.
7. Simon D, Leger J, Fjellestad-Paulsen A, Crabbé R, Czernichow P, SGA Study Group. Intermittent recombinant growth hormone treatment in short children born small for gestational age: four-year results of a randomized trial of two different treatment regimens. Horm Res. 2006;66: 118-123.
8. Sawczenko A, Ballinger AB, CroftNM, Sanderson IR, Savage MO. Adult height in patients with early onset of Crohn's disease. Gut 2003;52:454-455; author reply 455.
9. Sawczenko A, Ballinger AB, Savage MO, Sanderson IR. Clinical features affecting final adult height in patients with pediatric-onset Crohn's disease. Pediatrics. 2006;118: 124-129.
10. Mason A, Malik S, McMillan M, et al. A prospective longitudinal study of growth and pubertal progress in adolescents with inflammatory bowel disease. Horm Res Paediatr. 2015;83:45-54.
11. MacRae VE, Wong SC, Farquharson C, Ahmed SF. Cytokine actions in growth disorders associated with pediatric chronic inflammatory diseases (review). Int J Mol Med. 2006;18:1011-1018.
12. Sanderson IR. Growth problems in children with IBD. Nat Rev Gastroenterol Hepatol. 2014;11:601-610.
13. Wong SC, Macrae VE, McGrogan P, Ahmed SF. The role of pro-inflammatory cytokines in inflammatory bowel disease growth retardation. J Pediatr Gastroenterol Nutr. 2006;43:144-155.
14. Rogol AD, Roemmich JN, Clark PA. Growth at puberty. J Adolesc Health. 2002;31:192-200.
15. Tanner JM, Davies PS. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr. 1985;107:317-329.
16. Tanner JM, Whitehouse RH, Marubini E, Resele LF. The adolescent growth spurt of boys and girls of the Harpenden growth study. Ann Hum Biol. 1976;3:109-126.
17. Borzutzky A, Martinez-Aguayo A. Accelerated carpal bone maturation in juvenile idiopathic arthritis: pitfall for bone age measurement. J Pediatr Endocrinol Metab. 2011; 24:551.
18. Malik S, Mason A, Bakhshi A, et al. Growth in children receiving contemporary disease specific therapy for Crohn's disease. Arch Dis Child. 2012;97:698-703.
19. Roth J, Bechtold S, Borte G, Dressler F, Girschick HJ, Borte M. Osteoporosis in juvenile idiopathic arthritis-a practical approach to diagnosis and therapy. Eur J Pediatr. 2007; 166:775-784.
20. Pappa H, Thayu M, Sylvester F, Leonard M, Zemel B, Gordon C. Skeletal health of children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2011;53:11-25.
21. Kearsley-Fleet L, Hyrich KL, Davies R, Lunt M, Southwood TR. Growth in children and adolescents with juvenile idiopathic arthritis over 2 years of treatment with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Rheumatology (Oxford). 2015;54:1279-1285.
22. Kearsley-Fleet L, Hyrich KL, Davies R, Lunt M, Southwood TR. Growth in children and adolescents with juvenile idiopathic arthritis over 2 years of treatment with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Rheumatology (Oxford). 2015;54:1279-1285.
23. Cheung MS, Bridges NA, Prasad SA, et al. Growth in children with cystic fibrosis-related diabetes. Pediatr Pulmonol. 2009;44:1223-1225.
24. Hameed S, Morton JR, Field PI, et al. Once daily insulin detemir in cystic fibrosis with insulin deficiency. Arch Dis Child. 2012;97:464-467.
25. O'Riordan SM, Dattani MT, Hindmarsh PC. Cystic fibrosis-related diabetes in childhood. Horm Res Paediatr. 2010;73:15-24.
26. Wong SC, Catto-Smith AG, Zacharin M. Pathological fractures in paediatric patients with inflammatory bowel disease. Eur J Pediatr. 2014;173:141-151.
27. Stalvey MS, Clines GA. Cystic fibrosis-related bone disease: insights into a growing problem. Curr Opin Endocrinol Diabetes Obes. 2013;20:547-552.
28. Brabnikova Maresova K. Secondary osteoporosis in patients with juvenile idiopathic arthritis. J Osteoporos. 2011;2011:569417.
29. Franklin SL, Geffner ME. Growth hormone: the expansion of available products and indications. Pediatr Clin North Am. 2011;58:1141-1165, x.
30. Hughes IP, Choong CS, Harris M, et al. Growth hormone treatment for Turner syndrome in Australia reveals that younger age and increased dose interact to improve response. Clin Endocrinol (Oxf). 2011;74:473-480.
31. Wasniewska M, Aversa T, Mazzanti L, et al. Adult height in girls with Turner syndrome treated from before 6 years of age with a fixed per kilogram GH dose. Eur J Endocrinol. 2013;169:439-443.
32. Wasniewska M, De Luca F, Bergamaschi R, et al. Early treatment withGHalone in Turner syndrome: prepubertal catch-up growth and waning effect. Eur J Endocrinol. 2004;151:567-572.
33. Lem AJ, van der Kaay DC, de Ridder MA, et al. Adult height in short children born SGA treated with growth hormone and gonadotropin releasing hormone analog: results of a randomized, dose-response GH trial. J Clin Endocrinol Metab. 2012;97:4096-4105.
34. Ranke MB, Martin DD, Ehehalt S, et al. Short children with low birth weight born either small for gestational age or average for gestational age show similar growth response and changes in insulin-like growth factor-1 to growth hormone treatment during the first prepubertal year. Horm Res Paediatr. 2011;76:104-112.
35. Hughes IP, Harris M, Choong CS, et al. Growth hormone regimens in Australia: analysis of the first 3 years of treatment for idiopathic growth hormone deficiency and idiopathic short stature. Clin Endocrinol (Oxf). 2012;77: 62-71.
36. Blum WF, Ross JL, Zimmermann AG, et al. GHtreatment to final height produces similar height gains in patients with SHOX deficiency and Turner syndrome: results of a multicenter trial. J Clin Endocrinol Metab. 2013;98: E1383-E1392.
37. Bakker NE, Kuppens RJ, Siemensma EP, et al. Eight years of growth hormone treatment in children with Prader-Willi syndrome: maintaining the positive effects. J Clin Endocrinol Metab. 2013;98:4013-4022.
38. Hodson EM, Willis NS, Craig JC. Growth hormone for children with chronic kidney disease. Cochrane Database Syst Rev. 2012;2:CD003264.
39. Bechtold S, Ripperger P, Dalla Pozza R, et al. Growth hormone increases final height in patients with juvenile idiopathic arthritis: data from a randomized controlled study. J Clin Endocrinol Metab. 2007;92:3013-3018.
40. Lui JC, Nilsson O, Baron J. Recent research on the growth plate: recent insights into the regulation of the growth plate. J Mol Endocrinol. 2014;53:T1-T9.
41. Kaplan SA, Cohen P. The somatomedin hypothesis 2007: 50 years later. J Clin Endocrinol Metab. 2007;92:4529-4535.
42. Roselló-Díez A, Joyner AL. Regulation of long bone growth in vertebrates; it is time to catch up. Endocr Rev. 2015;36:646-680.
43. Schlechter NL, Russell SM, Spencer EM, Nicoll CS. Evidence suggesting that the direct growth-promoting effect of growth hormone on cartilage in vivo is mediated by local production of somatomedin. Proc Natl Acad Sci USA. 1986;83:7932-7934.
44. Salmon WD Jr, Burkhalter VJ. Stimulation of sulfate and thymidine incorporation into hypophysectomized rat cartilage by growth hormone and insulin-like growth factor-I in vitro: the somatomedin hypothesis revisited. J Lab Clin Med. 1997;129:430-438.
45. Lupu F, Terwilliger JD, Lee K, Segre GV, Efstratiadis A. Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev Biol. 2001;229:141-162.
46. Wang J, Zhou J, Cheng CM, Kopchick JJ, Bondy CA. Evidence supporting dual, IGF-I-independent and IGF-Idependent, roles for GH in promoting longitudinal bone growth. J Endocrinol. 2004;180:247-255.
47. Sims NA, Clément-Lacroix P, Da Ponte F, et al. Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of Stat5. J Clin Invest. 2000;106:1095-1103.
48. Mohan S, Richman C, Guo R, et al. Insulin-like growth factor regulates peak bone mineral density in mice by both growth hormone-dependent and-independent mechanisms. Endocrinology. 2003;144:929-936.
49. Hutchison MR, Bassett MH, White PC. Insulin-like growth factor-I and fibroblast growth factor, but not growth hormone, affect growth plate chondrocyte proliferation. Endocrinology. 2007;148:3122-3130.
50. Wang Y, Nishida S, Sakata T, et al. Insulin-like growth factor-I is essential for embryonic bone development. Endocrinology. 2006;147:4753-4761.
51. Yakar S, Isaksson O. Regulation of skeletal growth and mineral acquisition by the GH/IGF-1 axis: lessons from mouse models [published online September 28, 2015]. Growth Horm IGF Res. doi:10.1016/j.ghir.2015.09.004.
52. Yakar S, Liu JL, Stannard B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA. 1999;96:7324-7329.
53. Yakar S, Rosen CJ, Bouxsein ML, et al. Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism. FASEB J. 2009;23:709-719.
54. Govoni KE, Lee SK, Chung YS, et al. Disruption of insulinlike growth factor-I expression in type IIαI collagen-expressing cells reduces bone length and width in mice. Physiol Genomics. 2007;30:354-362.
55. Wu Y, Sun H, Yakar S, LeRoith D. Elevated levels of insulin-like growth factor (IGF)-I in serum rescue the severe growth retardation of IGF-I null mice. Endocrinology. 2009;150:4395-4403.
56. Wu S, Yang W, De Luca F. Insulin-like growth factorindependent effects of growth hormone on growth plate chondrogenesis and longitudinal bone growth. Endocrinology. 2015;156:2541-2551.
57. Sundström K, Cedervall T, Ohlsson C, Camacho-Hübner C, Sävendahl L. Combined treatment with GH and IGF-I: additive effect on cortical bone mass but not on linear bone growth in female rats. Endocrinology. 2014;155:4798-4807.
58. Elis S, WuY, CourtlandHW, et al. Unbound (bioavailable) IGF1 enhances somatic growth. Dis Model Mech. 2011; 4:649-658.
59. Nilsson O, Marino R, De Luca F, Phillip M, Baron J. Endocrine regulation of the growth plate. Horm Res. 2005; 64:157-165.
60. Kember NF. Cell population kinetics of bone growth: the first ten years of autoradiographic studies with tritiated thymidine. Clin Orthop Relat Res. 1971;76:213-230.
61. Abad V, Meyers JL, Weise M, et al. The role of the resting zone in growth plate chondrogenesis. Endocrinology. 2002;143:1851-1857.
62. Kember NF, Walker KV. Control of bone growth in rats. Nature. 1971;229:428-429.
63. Hunziker EB. Mechanism of longitudinal bone growth and its regulation by growth plate chondrocytes. Microsc Res Tech. 1994;28:505-519.
64. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med. 1999;5:623-628.
65. Farnum CE, Wilsman NJ. Cellular turnover at the chondro-osseous junction of growth plate cartilage: analysis by serial sections at the light microscopical level. J Orthop Res. 1989;7:654-666.
66. Hunziker EB, Wagner J, Zapf J. Differential effects of insulin-like growth factor I and growth hormone on developmental stages of rat growth plate chondrocytes in vivo. J Clin Invest. 1994;93:1078-1086.
67. Reinecke M, Schmid AC, Heyberger-Meyer B, Hunziker EB, Zapf J. Effect of growth hormone and insulin-like growth factor I (IGF-I) on the expression of IGF-I messenger ribonucleic acid and peptide in rat tibial growth plate and articular chondrocytes in vivo. Endocrinology. 2000; 141:2847-2853.
68. Farquharson C, Ahmed SF. Inflammation and linear bone growth: the inhibitory role of SOCS2 on GH/IGF-1 signaling. Pediatr Nephrol. 2013;28:547-556.
69. Macrae VE, Horvat S, Pells SC, et al. Increased bone mass, altered trabecular architecture and modified growth plate organization in the growing skeleton of SOCS2 deficient mice. J Cell Physiol. 2009;218:276-284.
70. Dobie R, AhmedSF, StainesKA, et al. Increased linear bone growth by GH in the absence of SOCS2 is independent of IGF-1. J Cell Physiol. 2015;230:2796-2806.
71. MacRae VE, Farquharson C, Ahmed SF. The restricted potential for recovery of growth plate chondrogenesis and longitudinal bone growth following exposure to pro-inflammatory cytokines. J Endocrinol. 2006;189:319-328.
72. Aizawa T, Kon T, Einhorn TA, Gerstenfeld LC. Induction of apoptosis in chondrocytes by tumor necrosis factor-α. J Orthop Res. 2001;19:785-796.
73. Mårtensson K, Chrysis D, Sävendahl L. Interleukin-1β and TNF-α act in synergy to inhibit longitudinal growth in fetal rat metatarsal bones. J Bone Miner Res. 2004;19:1805-1812.
74. Choukair D, Hügel U, Sander A, Uhlmann L, TönshoffB. Inhibition of IGF-I-related intracellular signaling pathways by proinflammatory cytokines in growth plate chondrocytes. Pediatr Res. 2014;76:245-251.
75. Goldring MB, Birkhead J, Sandell LJ, Kimura T, Krane SM. Interleukin 1 suppresses expression of cartilage-specific types II and IX collagens and increases types I and III collagens in human chondrocytes. J Clin Invest. 1988;82: 2026-2037.
76. Horiguchi M, Akiyama H, Ito H, Shigeno C, Nakamura T. Tumour necrosis factor-α up-regulates the expression of BMP-4 mRNA but inhibits chondrogenesis in mouse clonal chondrogenic EC cells, ATDC5. Cytokine. 2000; 12:526-530.
77. Ye W, Ma RF, Ding Y, et al. Effect of interleukin-6 on the chondrocytes in the cartilage endplate of rabbits in vitro [in Chinese]. Nan Fang Yi Ke Da Xue Xue Bao. 2007;27: 1187-1189.
78. Horan J, Dean DD, Kieswetter K, Schwartz Z, Boyan BD. Evidence that interleukin-1, but not interleukin-6, affects costochondral chondrocyte proliferation, differentiation, and matrix synthesis through an autocrine pathway. JBone Miner Res. 1996;11:1119-1129.
79. Nakajima S, Naruto T, Miyamae T, et al. Interleukin-6 inhibits early differentiation of ATDC5 chondrogenic progenitor cells. Cytokine. 2009;47:91-97.
80. Legendre F, Dudhia J, Pujol JP, Bogdanowicz P.JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of Sox9 expression. J Biol Chem. 2003;278:2903-2912.
81. Fernandez-Vojvodich P, Zaman F, Sävendahl L. Interleukin-6 acts locally on the growth plate to impair bone growth [published online July 17, 2013]. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-204112.
82. Fernandez-Vojvodich P, Karimian E, Sävendahl L. The biologics anakinra and etanercept prevent cytokine-induced growth retardation in cultured fetal rat metatarsal bones. Horm Res Paediatr. 2011;76:278-285.
83. Fernandez-Vojvodich P, Palmblad K, Karimian E, Andersson U, Sävendahl L. Pro-inflammatory cytokines produced by growth plate chondrocytes may act locally to modulate longitudinal bone growth. Horm Res Paediatr. 2012;77:180-187.
84. Simsa-Maziel S, Zaretsky J, Reich A, Koren Y, Shahar R, Monsonego-Ornan E. IL-1RI participates in normal growth plate development and bone modeling. Am J Physiol Endocrinol Metab. 2013;305:E15-E21.
85. Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child. 2003;88:995-1000.
86. MacRae VE, Wong SC, Smith W, et al. Cytokine profiling and in vitro studies of murine bone growth using biological fluids from children with juvenile idiopathic arthritis. Clin Endocrinol (Oxf). 2007;67:442-448.
87. Broussard SR, McCusker RH, Novakofski JE, et al. IL-1β impairs insulin-like growth factor I-induced differentiation and downstream activation signals of the insulin-like growth factor I receptor in myoblasts. J Immunol. 2004; 172:7713-7720.
88. Kenchappa P, Yadav A, Singh G, Nandana S, Banerjee K. Rescue ofTNFα-inhibited neuronal cells by IGF-1 involves Akt and c-Jun N-terminal kinases. J Neurosci Res. 2004; 76:466-474.
89. Matsumoto T, Tsukazaki T, Enomoto H, Iwasaki K, Yamashita S. Effects of interleukin-1 β on insulin-like growth factor-I autocrine/paracrine axis in cultured rat articular chondrocytes. Ann Rheum Dis. 1994;53:128-133.
90. ShenWH, ZhouJH, Broussard SR, FreundGG, Dantzer R, Kelley KW. Proinflammatory cytokines block growth of breast cancer cells by impairing signals from a growth factor receptor. Cancer Res. 2002;62:4746-4756.
91. Strle K, Broussard SR, McCusker RH, et al. Proinflammatory cytokine impairment of insulin-like growth factor I-induced protein synthesis in skeletal muscle myoblasts requires ceramide. Endocrinology. 2004;145:4592-4602.
92. Macrae VE, Ahmed SF, Mushtaq T, Farquharson C. IGF-I signalling in bone growth: inhibitory actions of dexamethasone and IL-1β. Growth Horm Igf Res. 2007;17:435-439.
93. Li WQ, Dehnade F, Zafarullah M. Oncostatin M-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires Janus kinase/STAT signaling pathway. J Immunol. 2001; 166:3491-3498.
94. Boisclair YR, Wang J, Shi J, Hurst KR, Ooi G. Role of the suppressor of cytokine signaling-3 in mediating the inhibitory effects of interleukin-1β on the growth hormone-dependent transcription of the acid-labile subunit gene in liver cells. J Biol Chem. 2000;275:3841-3847.
95. Liu X, Shi Q, Sigmund C. Interleukin-1β attenuates renin gene expression via a mitogen-activated protein kinase kinase-extracellular signal-regulated kinase and signal transducer and activator of transcription 3-dependent mechanism in As4.1 cells. Endocrinology. 2006;147: 6011-6018.
96. Shi H, Tzameli I, Bjørbaek C, Flier JS. Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling. J Biol Chem. 2004;279:34733-34740.
97. Troib A, Landau D, Kachko L, Rabkin R, Segev Y. Epiphyseal growth plate growth hormone receptor signaling is decreased in chronic kidney disease-related growth retardation. Kidney Int. 2013;84:940-949.
98. Denson LA, Held MA, Menon RK, Frank SJ, Parlow AF, Arnold DL. Interleukin-6 inhibits hepatic growth hormone signaling via upregulation of Cis and Socs-3. Am J Physiol Gastrointest Liver Physiol. 2003;284:G646-G654.
99. Pass C, MacRae VE, Ahmed SF, Farquharson C. Inflammatory cytokines and the GH/IGF-I axis: novel actions on bone growth. Cell Biochem Funct. 2009;27:119-127.
100. Pass C, MacRae VE, Huesa C, Faisal Ahmed S, Farquharson C. SOCS2 is the critical regulator of GH action in murine growth plate chondrogenesis. J Bone Miner Res. 2012;27:1055-1066.
101. Ahmed SF, Farquharson C. The effect of GH and IGF1 on linear growth and skeletal development and their modulation by SOCS proteins. J Endocrinol. 2010;206:249-259.
102. Jantzen HM, Strähle U, Gloss B, et al. Cooperativity of glucocorticoid response elements located far upstream of the tyrosine aminotransferase gene. Cell. 1987;49:29-38.
103. Beato M, Sánchez-Pacheco A. Interaction of steroid hormone receptors with the transcription initiation complex. Endocr Rev. 1996;17:587-609.
104. McKay LI, Cidlowski JA. Molecular control of immune/inflammatory responses: interactions between nuclear factor-κ B and steroid receptor-signaling pathways. Endocr Rev. 1999;20:435-459.
105. Chrysis D, Zaman F, Chagin AS, Takigawa M, Sävendahl L. Dexamethasone induces apoptosis in proliferative chondrocytes through activation of caspases and suppression of the Akt-phosphatidylinositol 3'-kinase signaling pathway. Endocrinology. 2005;146:1391-1397.
106. Luo JM, Murphy LJ. Dexamethasone inhibits growth hormone induction of insulin-like growth factor-I (IGF-I) messenger ribonucleic acid (mRNA) in hypophysectomized rats and reduces IGF-I mRNA abundance in the intact rat. Endocrinology. 1989;125:165-171.
107. Klaus G, Jux C, Fernandez P, Rodriguez J, Himmele R, Mehls O. Suppression of growth plate chondrocyte proliferation by corticosteroids. Pediatr Nephrol. 2000;14: 612-615.
108. Giustina A, Buffoli MG, Bussi AR, et al. Comparative effect of clonidine and growth hormone (GH)-releasing hormone on GH secretion in adult patients on chronic glucocorticoid therapy. Horm Metab Res. 1992;24:240-243.
109. Giustina A, Veldhuis J. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998;19:717-797.
110. Fujita T, Fukuyama R, Enomoto H, Komori T. Dexamethasone inhibits insulin-induced chondrogenesis of ATDC5 cells by preventing PI3K-Akt signaling and DNA binding of Runx2. J Cell Biochem. 2004;93:374-383.
111. Mushtaq T, Bijman P, Ahmed SF, Farquharson C. Insulinlike growth factor-I augments chondrocyte hypertrophy and reverses glucocorticoid-mediated growth retardation in fetal mice metatarsal cultures. Endocrinology. 2004; 145:2478-2486.
112. Baron J, Huang Z, Oerter KE, Bacher JD, Cutler GB Jr. Dexamethasone acts locally to inhibit longitudinal bone growth in rabbits. Am J Physiol. 1992;263:E489-E492.
113. Silvestrini G, Mocetti P, Ballanti P, Di Grezia R, Bonucci E. Cytochemical demonstration of the glucocorticoid receptor in skeletal cells of the rat. Endocr Res. 1999;25: 117-128.
114. AbuEO, Horner A, Kusec V, Triffitt JT, Compston JE. The localization of the functional glucocorticoid receptor α in human bone. J Clin Endocrinol Metab. 2000;85:883-889.
115. Owen HC, Miner JN, Ahmed SF, Farquharson C. The growth plate sparing effects of the selective glucocorticoid receptor modulator, AL-438. Mol Cell Endocrinol. 2007; 264:164-170.
116. Chrysis D, Ritzen EM, Sävendahl L. Growth retardation induced by dexamethasone is associated with increased apoptosis of the growth plate chondrocytes. J Endocrinol. 2003;176:331-337.
117. Zhao Y, Zuo Y, Huo H, Xiao Y, Yang X, Xin D. Dexamethasone reduces ATDC5 chondrocyte cell viability by inducing autophagy. Mol Med Rep. 2014;9:923-927.
118. Siebler T, Robson H, Shalet SM, Williams GR. Dexamethasone inhibits and thyroid hormone promotes differentiation of mouse chondrogenic ATDC5 cells. Bone. 2002; 31:457-464.
119. Mushtaq T, Farquharson C, Seawright E, Ahmed SF. Glucocorticoid effects on chondrogenesis, differentiation and apoptosis in the murine ATDC5 chondrocyte cell line. J Endocrinol. 2002;175:705-713.
120. Negishi Y, Ui N, Nakajima M, et al. p21cip-1/SDI-1/WAF-1 Gene is involved in chondrogenic differentiation of ATDC5 cells in vitro. J Biol Chem. 2001;276:33249-33256.
121. Owen HC, Ahmed SF, Farquharson C. Chondrocyte p21(WAF1/CIP1) expression is increased by dexamethasone but does not contribute to dexamethasone-induced growth retardation in vivo. Calcif Tissue Int. 2009;85: 326-334.
122. Emons JA, Marino R, Nilsson O, et al. The role of p27Kip1 in the regulation of growth plate chondrocyte proliferation in mice. Pediatr Res. 2006;60:288-293.
123. Zaman F, Chrysis D, Huntjens K, Fadeel B, Sävendahl L. Ablation of the pro-apoptotic protein Bax protects mice from glucocorticoid-induced bone growth impairment. PLoS One. 2012;7:e33168.
124. Zaman F, Chrysis D, Huntjens K, et al. Dexamethasone differentially regulates Bcl-2 family proteins in human proliferative chondrocytes: role of pro-apoptotic Bid. Toxicol Lett. 2014;224:196-200.
125. James CG, Ulici V, Tuckermann J, Underhill TM, Beier F. Expression profiling of Dexamethasone-treated primary chondrocytes identifies targets of glucocorticoid signalling in endochondral bone development. BMC Genomics. 2007;8:205.
126. Owen HC, Roberts SJ, Ahmed SF, Farquharson C. Dexamethasone-induced expression of the glucocorticoid response gene lipocalin 2 in chondrocytes. Am J Physiol Endocrinol Metab. 2008;294:E1023-E1034.
127. Kym PR, Kort ME, Coghlan MJ, et al. Nonsteroidal selective glucocorticoid modulators: the effect of C-10 substitution on receptor selectivity and functional potency of 5-allyl-2, 5-dihydro-2, 2, 4-trimethyl-1H-[1]benzopyrano [3, 4-f]quinolines. J Med Chem. 2003;46:1016-1030.
128. Ayroldi E, Macchiarulo A, Riccardi C. Targeting glucocorticoid side effects: selective glucocorticoid receptor modulator or glucocorticoid-induced leucine zipper? A perspective. FASEB J. 2014;28:5055-5070.
129. Coghlan MJ, Jacobson PB, Lane B, et al. A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects. Mol Endocrinol. 2003;17:860-869.
130. Boersma B, Wit JM. Catch-up growth. Endocr Rev. 1997; 18:646-661.
131. Lui JC, Baron J. Effects of glucocorticoids on the growth plate. Endocr Dev. 2011;20:187-193.
132. Prader A, Tanner JM, von Harnack G. Catch-up growth following illness or starvation. An example of developmental canalization in man. J Pediatr. 1963;62:646-659.
133. Boersma B, Rikken B, Wit JM. Catch-up growth in early treated patients with growth hormone deficiency. Dutch Growth Hormone Working Group. Arch Dis Child. 1995; 72:427-431.
134. Damen GM, Boersma B, Wit JM, Heymans HS. Catch-up growth in 60 children with celiac disease. J Pediatr Gastroenterol Nutr. 1994;19:394-400.
135. Baron J, Klein KO, Yanovski JA, et al. Induction of growth plate cartilage ossification by basic fibroblast growth factor. Endocrinology. 1994;135:2790-2793.
136. Baron J, Klein KO, Colli MJ, et al. Catch-up growth after glucocorticoid excess: a mechanism intrinsic to the growth plate. Endocrinology. 1994;135:1367-1371.
137. Gafni RI, Weise M, Robrecht DT, et al. Catch-up growth is associated with delayed senescence of the growth plate in rabbits. Pediatr Res. 2001;50:618-623.
138. Ballinger AB, Azooz O, El-Haj T, Poole S, Farthing MJ. Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model of colitis. Gut. 2000;46:694-700.
139. Otley AR, Russell RK, Day AS. Nutritional therapy for the treatment of pediatric Crohn's disease. Expert Rev Clin Immunol. 2010;6:667-676.
140. Tannenbaum GS, Rorstad O, Brazeau P. Effects of prolonged food deprivation on the ultradian growth hormone rhythm and immunoreactive somatostatin tissue levels in the rat. Endocrinology. 1979;104:1733-1738.
141. Straus DS, Takemoto CD. Effect of fasting on insulin-like growth factor-I (IGF-I) and growth hormone receptor mRNAlevels and IGF-I gene transcription in rat liver. Mol Endocrinol. 1990;4:91-100.
142. Bornfeldt KE, Arnqvist HJ, Enberg B, Mathews LS, Norstedt G. Regulation of insulin-like growth factor-I and growth hormone receptor gene expression by diabetes and nutritional state in rat tissues. J Endocrinol. 1989;122: 651-656.
143. Bang P, Brismar K, Rosenfeld RG, Hall K. Fasting affects serum insulin-like growth factors (IGFs) and IGF-binding proteins differently in patients with noninsulin-dependent diabetes mellitus versus healthy nonobese and obese subjects. J Clin Endocrinol Metab. 1994;78:960-967.
144. Counts DR, Gwirtsman H, Carlsson LM, Lesem M, Cutler GB Jr. The effect of anorexia nervosa and refeeding on growth hormone-binding protein, the insulin-like growth factors (IGFs), and the IGF-binding proteins. J Clin Endocrinol Metab. 1992;75:762-767.
145. Kubicky RA, Wu S, Kharitonenkov A, De Luca F. Role of fibroblast growth factor 21 (FGF21) in undernutritionrelated attenuation of growth in mice. Endocrinology. 2012;153:2287-2295.
146. Inagaki T, Dutchak P, Zhao G, et al. Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21. Cell Metab. 2007;5:415-425.
147. Reitman ML. FGF21: a missing link in the biology of fasting. Cell Metab. 2007;5:405-407.
148. Inagaki T, Lin VY, Goetz R, MohammadiM, Mangelsdorf DJ, Kliewer SA. Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab. 2008;8: 77-83.
149. Wu S, Grunwald T, Kharitonenkov A, Dam J, Jockers R, De Luca F. Increased expression of fibroblast growth factor 21 (FGF21) during chronic undernutrition causes growth hormone insensitivity in chondrocytes by inducing leptin receptor overlapping transcript (LEPROT) and leptin receptor overlapping transcript-like 1 (LEPROTL1) expression. J Biol Chem. 2013;288:27375-27383.
150. Pando R, Shtaif B, Phillip M, Gat-Yablonski G. A serum component mediates food restriction-induced growth attenuation. Endocrinology. 2014;155:932-940.
151. De Benedetti F, Alonzi T, Moretta A, et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest. 1997;99:643-650.
152. De Benedetti F, Meazza C, Oliveri M, et al. Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology. 2001;142:4818-4826.
153. De Benedetti F, Pignatti P, Vivarelli M, et al. In vivo neutralization of human IL-6 (hIL-6) achieved by immunization of hIL-6-transgenic mice with a hIL-6 receptor antagonist. J Immunol. 2001;166:4334-4340.
154. López-Calderón A, Soto L, Martín AI. Chronic inflammation inhibitsGHsecretion and alters the serum insulin-like growth factor system in rats. Life Sci. 1999;65:2049-2060.
155. IbáñezDeCáceres I, Holly JM, Priego T, Martín AI, López-Calderón A, Villanúa MA. Arthritis-induced increase in serum levels of IGF-binding protein-3 in rats is secondary to the decrease in its proteolytic activity. J Endocrinol. 2002;173:357-364.
156. Ibañez De Cáceres I, Villanúa MA, Soto L, Martin AI, López-Calderón A. IGF-I and IGF-I-binding proteins in rats with adjuvant-induced arthritis given recombinant human growth hormone. J Endocrinol. 2000;165:537-544.
157. Granado M, Martín AI, Villanúa MA, López-Calderón A. Experimental arthritis inhibits the insulin-like growth factor-I axis and induces muscle wasting through cyclooxygenase-2 activation. Am J Physiol Endocrinol Metab. 2007;292:E1656-E1665.
158. Crist DM, Peake GT, Mackinnon LT, Sibbitt WL Jr, Kraner JC. Exogenous growth hormone treatment alters body composition and increases natural killer cell activity in women with impaired endogenous growth hormone secretion. Metabolism. 1987;36:1115-1117.
159. Ballinger A. Fundamental mechanisms of growth failure in inflammatory bowel disease. Horm Res. 2002;58(suppl 1): 7-10.
160. Koniaris SG, Fisher SE, Rubin CT, Chawla A. Experimental colitis impairs linear bone growth independent of nutritional factors. J Pediatr Gastroenterol Nutr. 1997;25: 137-141.
161. Sawczenko A, Azooz O, Paraszczuk J, et al. Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the-174 IL-6 G/C polymorphism in children. Proc Natl Acad Sci USA. 2005;102:13260-13265.
162. Azooz OG, Farthing MJ, Savage MO, Ballinger AB. Delayed puberty and response to testosterone in a rat model of colitis. Am J Physiol Regul Integr Comp Physiol. 2001; 281:R1483-R1491.
163. Deboer MD, Li Y. Puberty is delayed in male mice with dextran sodium sulfate colitis out of proportion to changes in food intake, body weight, and serum levels of leptin. Pediatr Res. 2011;69:34-39.
164. DeBoer MD, Li Y, Cohn S. Colitis causes delay in puberty in female mice out of proportion to changes in leptin and corticosterone. J Gastroenterol. 2010;45:277-284.
165. Kalra PS, FuentesM, Sahu A, Kalra SP. Endogenous opioid peptides mediate the interleukin-1-induced inhibition of the release of luteinizing hormone (LH)-releasing hormone and LH. Endocrinology. 1990;127:2381-2386.
166. Rivier C, Vale W. Cytokines act within the brain to inhibit luteinizing hormone secretion and ovulation in the rat. Endocrinology. 1990;127:849-856.
167. Nappi RE, Rivest S. Effect of immune and metabolic challenges on the luteinizing hormone-releasing hormone neuronal system in cycling female rats: an evaluation at the transcriptional level. Endocrinology. 1997;138:1374-1384.
168. Morales V, Santana P, Díaz R, et al. Intratesticular delivery of tumor necrosis factor-α and ceramide directly abrogates steroidogenic acute regulatory protein expression and Leydig cell steroidogenesis in adult rats. Endocrinology. 2003; 144:4763-4772.
169. Rosenberg LA, Schluchter MD, Parlow AF, Drumm ML. Mouse as a model of growth retardation in cystic fibrosis. Pediatr Res. 2006;59:191-195.
170. Hodges CA, Grady BR, Mishra K, Cotton CU, Drumm ML. Cystic fibrosis growth retardation is not correlated with loss of Cftr in the intestinal epithelium. Am J Physiol Gastrointest Liver Physiol. 2011;301:G528-G536.
171. Rogan MP, Reznikov LR, Pezzulo AA, et al. Pigs and humans with cystic fibrosis have reduced insulin-like growth factor 1 (IGF1) levels at birth. Proc Natl Acad Sci USA. 2010;107:20571-20575.
172. López-Menduiña M, Martín AI, Castillero E, Villanúa MA, López-Calderón A. Short-term growth hormone or IGF-I administration improves the IGF-IGFBP system in arthritic rats. Growth Horm Igf Res. 2012;22:22-29.
173. Williams KL, Fuller CR, Dieleman LA, et al. Enhanced survival and mucosal repair after dextran sodium sulfateinduced colitis in transgenic mice that overexpress growth hormone. Gastroenterology. 2001;120:925-937.
174. Han X, Sosnowska D, Bonkowski EL, Denson LA. Growth hormone inhibits signal transducer and activator of transcription 3 activation and reduces disease activity in murine colitis. Gastroenterology. 2005;129:185-203.
175. Christensen H, Flyvbjerg A, Orskov H, Laurberg S. Effect of growth hormone on the inflammatory activity of experimental colitis in rats. Scand J Gastroenterol. 1993;28: 503-511.
176. DiFedele LM, He J, Bonkowski EL, et al. Tumor necrosis factor α blockade restores growth hormone signaling in murine colitis. Gastroenterology. 2005;128:1278-1291.
177. D'Mello S, Trauernicht A, Ryan A, et al. Innate dysfunction promotes linear growth failure in pediatric Crohn's disease and growth hormone resistance in murine ileitis. Inflamm Bowel Dis. 2012;18:236-245.
178. Petty RE, Southwood TR, Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol. 1998;25:1991-1994.
179. Prakken BJ, Albani S. Using biology of disease to understand and guide therapy of JIA. Best Pract Res Clin Rheumatol. 2009;23:599-608.
180. Berkun Y, Padeh S. Environmental factors and the geoepidemiology of juvenile idiopathic arthritis. Autoimmun Rev. 2010;9:A319-A324.
181. Foeldvari I, Bidde M. Validation of the proposed ILAR classification criteria for juvenile idiopathic arthritis. International League of Associations for Rheumatology. J Rheumatol. 2000;27:1069-1072.
182. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001 J Rheumatol. 2004;31:390-392.
183. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011;63:465-482.
184. Eberhard BA, Sison MC, Gottlieb BS, Ilowite NT. Comparison of the intraarticular effectiveness of triamcinolone hexacetonide and triamcinolone acetonide in treatment of juvenile rheumatoid arthritis. J Rheumatol. 2004;31:2507-2512.
185. Eberhard BA, Ilowite NT, Sison C. A dose schedule for intraarticular steroids in juvenile arthritis. J Rheumatol. 2012;39:374-376.
186. Papadopoulou C, Kostik M, Gonzalez-Fernandez MI, et al. Delineating the role of multiple intraarticular corticosteroid injections in the management of juvenile idiopathic arthritis in the biologic era. Arthritis Care Res (Hoboken). 2013;65:1112-1120.
187. Sherry DD, Stein LD, Reed AM, Schanberg LE, Kredich DW. Prevention of leg length discrepancy in young children with pauciarticular juvenile rheumatoid arthritis by treatment with intraarticular steroids. Arthritis Rheum. 1999;42:2330-2334.
188. Habib GS. Systemic effects of intra-articular corticosteroids. Clin Rheumatol. 2009;28:749-756.
189. Hameed R, Zacharin MR. Cushing syndrome, adrenal suppression and local corticosteroid use. J Paediatr Child Health. 2006;42:392-394.
190. Gondwe JS, Davidson JE, Deeley S, Sills J, Cleary AG. Secondary Cushing's syndrome in children with juvenile idiopathic arthritis following intra-articular triamcinolone acetonide administration. Rheumatology. 2005;44:1457-1458.
191. Kumar S, Singh RJ, Reed AM, Lteif AN. Cushing's syndrome after intra-articular and intradermal administration of triamcinolone acetonide in three pediatric patients. Pediatrics. 2004;113:1820-1824.
192. Huppertz HI, Tschammler A, Horwitz AE, Schwab KO. Intraarticular corticosteroids for chronic arthritis in children: efficacy and effects on cartilage and growth. J Pediatr. 1995;127:317-321.
193. Heuck C, Wolthers OD, Herlin T. Growth-suppressive effect of intra-articular glucocorticoids detected by knemometry. Horm Res. 1999;52:95-96.
194. Simon S, Whiffen J, Shapiro F. Leg-length discrepancies in monoarticular and pauciarticular juvenile rheumatoid arthritis. J Bone Joint Surg Am. 1981;63:209-215.
195. Wahezi DM, Ilowite NT. Juvenile idiopathic arthritis: an update on current pharmacotherapy and future perspectives. Expert Opin Pharmacother. 2013;14:975-989.
196. Dannecker GE, Quartier P. Juvenile idiopathic arthritis: classification, clinical presentation and current treatments. Horm Res. 2009;72(suppl 1):4-12.
197. Cassidy JT, Levinson JE, Bass JC, et al. A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis. Arthritis Rheum. 1986;29:274-281.
198. Minden K, Niewerth M, Listing J, et al. Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum. 2002;46:2392-2401.
199. Weiss JE, Ilowite NT. Juvenile idiopathic arthritis. Rheum Dis Clin North Am. 2007;33:441-470, vi.
200. Silverman E, Mouy R, Spiegel L, et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med. 2005;352:1655-1666.
201. Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med. 1992;326:1043-1049.
202. Lovell DJ, Giannini EH, ReiffA, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. NEngl J Med. 2000;342:763-769.
203. HorneffG, Schmeling H, Biedermann T, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63:1638-1644.
204. Lovell DJ, Ruperto N, GoodmanS, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359:810-820.
205. Vojvodich PF, Hansen JB, Andersson U, Sävendahl L, Hagelberg S. Etanercept treatment improves longitudinal growth in prepubertal children with juvenile idiopathic arthritis. J Rheumatol. 2007;34:2481-2485.
206. Tynjälä P, Lahdenne P, Vähäsalo P, Kautiainen H, Honkanen V. Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis. Ann Rheum Dis. 2006;65: 1044-1049.
207. Simon D, Fernando C, Czernichow P, Prieur AM. Linear growth and final height in patients with systemic juvenile idiopathic arthritis treated with longterm glucocorticoids. J Rheumatol. 2002;29:1296-1300.
208. Spiegel LR, Schneider R, Lang BA, et al. Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum. 2000;43:2402-2409.
209. Kimura Y, Pinho P, Walco G, et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2005;32:935-942.
210. de Benedetti F, Martini A. Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis? Arthritis Rheum. 2005;52:687-693.
211. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005;201:1479-1486.
212. Gattorno M, Piccini A, Lasigliè D, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008;58:1505-1515.
213. Zeft A, Hollister R, LaFleur B, et al. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. J Clin Rheumatol. 2009;15:161-164.
214. Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63: 545-555.
215. Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70:747-754.
216. de Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 1991;34: 1158-1163.
217. Woo P, Wilkinson N, Prieur AM, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2005;7:R1281-R1288.
218. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebocontrolled, withdrawal phase III trial. Lancet. 2008;371: 998-1006.
219. De Benedetti F, Brunner H, Ruperto N, et al. Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: results from a phase III trial. Arthritis Rheumatol. 2015;67:840-848.
220. Arvidsson LZ, Fjeld MG, Smith HJ, Flatø B, Ogaard B, Larheim TA. Craniofacial growth disturbance is related to temporomandibular joint abnormality in patients with juvenile idiopathic arthritis, but normal facial profile was also found at the 27-year follow-up. Scand J Rheumatol. 2010;39:373-379.
221. Carvalho RT, Braga FS, Brito F, Capelli Junior J, Figueredo CM, Sztajnbok FR. Temporomandibular joint alterations and their orofacial complications in patients with juvenile idiopathic arthritis. Rev Bras Reumatol. 2012;52:907-911.
222. Demant S, Hermann NV, Darvann TA, et al. 3D analysis of facial asymmetry in subjects with juvenile idiopathic arthritis. Rheumatology. 2011;50:586-592.
223. Liem JJ, Rosenberg AM. Growth patterns in juvenile rheumatoid arthritis. Clin Exp Rheumatol. 2003;21:663-668.
224. Saha MT, Verronen P, Laippala P, Lenko HL. Growth of prepubertal children with juvenile chronic arthritis. Acta Paediatrica. 1999;88:724-728.
225. Padeh S, Pinhas-Hamiel O, Zimmermann-Sloutskis D, Berkun Y. Children with oligoarticular juvenile idiopathic arthritis are at considerable risk for growth retardation. J Pediatr. 2011;159:832-837.e1-e2.
226. Gardner-Medwin JM, Killeen OG, Ryder CA, Bradshaw K, Johnson K. Magnetic resonance imaging identifies features in clinically unaffected knees predicting extension of arthritis in children with monoarthritis. J Rheumatol. 2006;33:2337-2343.
227. Polito C, Strano CG, Olivieri AN, et al. Growth retardation in non-steroid treated juvenile rheumatoid arthritis. Scand J Rheumatol. 1997;26:99-103.
228. Russo RA, Katsicas MM. Patients with very early-onset systemic juvenile idiopathic arthritis exhibit more inflammatory features and a worse outcome. J Rheumatol. 2013; 40:329-334.
229. Aggarwal B, BhallaAK, Singh S. Sexual maturation in boys with juvenile rheumatoid arthritis. Rheumatol Int. 2011; 31:1419-1421.
230. Maher SE, Ali FI. Sexual maturation in Egyptian boys and girls with juvenile rheumatoid arthritis. Rheumatol Int. 2013;33:2123-2126.
231. Aggarwal B, Bhalla AK, Singh S. Longitudinal growth at-tainments of Indian boys with juvenile rheumatoid arthritis. Rheumatol Int. 2011;31:635-640.
232. Rusconi R, Corona F, Grassi A, Carnelli V. Age at menarche in juvenile rheumatoid arthritis. J Pediatr Endocrinol Metab. 2003;16(suppl 2):285-288.
233. Umlawska W, Krzyzanowska M. Growth and menarche during remission in children with juvenile idiopathic arthritis. Med Wieku Rozwoj. 2009;13:194-200.
234. Ostensen M, Almberg K, Koksvik HS. Sex, reproduction, and gynecological disease in young adults with a history of juvenile chronic arthritis. J Rheumatol. 2000;27:1783-1787.
235. Gäre BA, Fasth A. The natural history of juvenile chronic arthritis: a population based cohort study. II. Outcome. J Rheumatol. 1995;22:308-319.
236. Zak M, Müller J, Karup Pedersen F. Final height, armspan, subischial leg length and body proportions in juvenile chronic arthritis. A long-term follow-up study. Horm Res. 1999;52:80-85.
237. Wang SJ, Yang YH, Lin YT, Yang CM, Chiang BL. Attained adult height in juvenile rheumatoid arthritis with or without corticosteroid treatment. Clin Rheumatol. 2002; 21:363-368.
238. Minden K. Adult outcomes of patients with juvenile idiopathic arthritis. Horm Res. 2009;72(suppl 1):20-25.
239. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: social function, relationships and sexual activity. Rheumatology. 2002;41:1440-1443.
240. Gutiérrez-Suárez R, Ruperto N, Gastaldi R, et al. A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1, 015 patients with juvenile-onset systemic lupus erythematosus. Arthritis Rheum. 2006;54:2989-2996.
241. Rygg M, Pistorio A, Ravelli A, et al. A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus. Ann Rheum Dis. 2012;71:511-517.
242. HaugenMA, HøyeraalHM, Larsen S, Gilboe IM, Trygg K. Nutrient intake and nutritional status in children with juvenile chronic arthritis. Scand J Rheumatol. 1992;21:165-170.
243. Saha MT, Ruuska T, Laippala P, Lenko HL. Growth of prepubertal children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1998;26:310-314.
244. Souza LS, Machado SH, Brenol CV, Brenol JC, Xavier RM. Growth velocity and interleukin 6 concentrations in juvenile idiopathic arthritis. J Rheumatol. 2008;35:2265-2271.
245. Tsatsoulis A, Siamopoulou A, Petsoukis C, Challa A, Bairaktari E, Seferiadis K. Study of growth hormone secretion and action in growth-retarded children with juvenile chronic arthritis (JCA). Growth Horm Igf Res. 1999;9: 143-149.
246. Allen RC, Jimenez M, Cowell CT. Insulin-like growth factor and growth hormone secretion in juvenile chronic arthritis. Ann Rheum Dis. 1991;50:602-606.
247. Davies UM, Jones J, Reeve J, et al. Juvenile rheumatoid arthritis. Effects of disease activity and recombinant human growth hormone on insulin-like growth factor 1, insulin-like growth factor binding proteins 1 and 3, and osteocalcin. Arthritis Rheum. 1997;40:332-340.
248. Bozzola E, Pagani S, Meazza C, et al. Changes in growth hormone receptor gene expression during therapy in children with juvenile idiopathic arthritis. Horm Res Paediatr. 2012;77:52-58.
249. Bechtold S, Beyerlein A, Ripperger P, et al. Total pubertal growth in patients with juvenile idiopathic arthritis treated with growth hormone: analysis of a single center. Growth Horm Igf Res. 2012;22:180-185.
250. Saha MT, Haapasaari J, Hannula S, Sarna S, Lenko HL. Growth hormone is effective in the treatment of severe growth retardation in children with juvenile chronic arthritis. Double blind placebo-controlled followup study. J Rheumatol. 2004;31:1413-1417.
251. Murray PG, Dattani MT, Clayton PE. Controversies in the diagnosis and management of growth hormone deficiency in childhood and adolescence. Arch Dis Child. 2016;101: 96-100.
252. Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society. J Clin Endocrinol Metab. 2000;85:3990-3993.
253. Soto L, Martín AI, Millán S, Vara E, López-Calderón A. Effects of endotoxin lipopolysaccharide administration on the somatotropic axis. J Endocrinol. 1998;159:239-246.
254. Wong SC, MacRae VE, Gracie JA, et al. Inflammatory cytokines in juvenile idiopathic arthritis: effects on physical growth and the insulin-like-growth factor axis. Growth Horm Igf Res. 2008;18:369-378.
255. Grote FK, Van Suijlekom-Smit LW, Mul D, et al. Growth hormone treatment in children with rheumatic disease, corticosteroid induced growth retardation, and osteopenia. Arch Dis Child. 2006;91:56-60.
256. Sarzi-Puttini P, Atzeni F, Schölmerich J, Cutolo M, Straub RH. Anti-TNF antibody treatment improves glucocorticoid induced insulin-like growth factor 1 (IGF1) resistance without influencing myoglobin and IGF1 binding proteins 1 and 3. Ann Rheum Dis. 2006;65:301-305.
257. Al-Mutair A, Bahabri S, Al-Mayouf S, Al-Ashwal A. Efficacy of recombinant human growth hormone in children with juvenile rheumatoid arthritis and growth failure. J Pediatr Endocrinol Metab. 2000;13:899-905.
258. Bechtold S, Ripperger P, Bonfig W, et al. Bone mass development and bone metabolism in juvenile idiopathic arthritis: treatment with growth hormone for 4 years. J Rheumatol. 2004;31:1407-1412.
259. Butenandt O. Rheumatoid arthritis and growth retardation in children: treatment with human growth hormone. Eur J Pediatr. 1979;130:15-28.
260. Davies UM, Rooney M, Preece MA, Ansell BM, Woo P. Treatment of growth retardation in juvenile chronic arthritis with recombinant human growth hormone. J Rheumatol. 1994;21:153-158.
261. Simon D, Lucidarme N, Prieur AM, Ruiz JC, Czernichow P. Effects on growth and body composition of growth hormone treatment in children with juvenile idiopathic arthritis requiring steroid therapy. J Rheumatol. 2003;30: 2492-2499.
262. Svantesson H. Treatment of growth failure with human growth hormone in patients with juvenile chronic arthritis. A pilot study. Clin Exp Rheumatol. 1991;9(suppl 6): 47-50.
263. Touati G, Prieur AM, Ruiz JC, Noel M, Czernichow P. Beneficial effects of one-year growth hormone administration to children with juvenile chronic arthritis on chronic steroid therapy. I. Effects on growth velocity and body composition [published correction appears in J Clin Endocrinol Metab. 1998;83(5):1547]. J Clin Endocrinol Metab. 1998;83:403-409.
264. Simon D, Touati G, Prieur AM, Ruiz JC, Czernichow P. Growth hormone treatment of short stature and metabolic dysfunction in juvenile chronic arthritis. Acta Paediatr Suppl. 1999;88:100-105.
265. Bechtold S, Ripperger P, Häfner R, Said E, Schwarz HP. Growth hormone improves height in patients with juvenile idiopathic arthritis: 4-year data of a controlled study. J Pediatr. 2003;143:512-519.
266. Bechtold S, Ripperger P, Mühlbayer D, et al. GH therapy in juvenile chronic arthritis: results of a two-year controlled study on growth and bone. J Clin Endocrinol Metab. 2001;86:5737-5744.
267. Kupfer SR, Underwood LE, Baxter RC, Clemmons DR. Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously. J Clin Invest. 1993;91:391-396.
268. Simon D, Prieur AM, Quartier P, Charles Ruiz J, Czernichow P. Early recombinant human growth hormone treatment in glucocorticoid-treated children with juvenile idiopathic arthritis: a 3-year randomized study. J Clin Endocrinol Metab. 2007;92:2567-2573.
269. Mehls O, Wühl E, TönshoffB, Schaefer F, Nissel R, Haffner D. Growth hormone treatment in short children with chronic kidney disease. Acta Paediatr. 2008;97: 1159-1164.
270. MahanJD, WaradyBA. Assessment and treatment of short stature in pediatric patients with chronic kidney disease: a consensus statement. Pediatr Nephrol. 2006;21:917-930.
271. Prader A, Largo RH, Molinari L, Issler C. Physical growth of Swiss children from birth to 20 years of age. First Zurich longitudinal study of growth and development. Helv Paediatr Acta Suppl. 1989;52:1-125.
272. Ranke MB, Lindberg A. Observed and predicted total pubertal growth during treatment with growth hormone in adolescents with idiopathic growth hormone deficiency, Turner syndrome, short stature, born small for gestational age and idiopathic short stature: KIGS analysis and review. Horm Res Paediatr. 2011;75:423-432.
273. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182-205.
274. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434.
275. Askling J, Grahnquist L, Ekbom A, Finkel Y. Incidence of paediatric Crohn's disease in Stockholm, Sweden. Lancet. 1999;354:1179.
276. Heyman MB, Kirschner BS, Gold BD, et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr. 2005;146: 35-40.
277. Hildebrand H, Finkel Y, Grahnquist L, Lindholm J, Ekbom A, Askling J. Changing pattern of paediatric inflammatory bowel disease in northern Stockholm 1990-2001. Gut. 2003;52:1432-1434.
278. Kugathasan S, Judd RH, Hoffmann RG, et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr. 2003;143: 525-531.
279. Wehkamp J, Salzman NH, Porter E, et al. Reduced Paneth cellα-defensins in ileal Crohn's disease. Proc Natl Acad Sci USA. 2005;102:18129-18134.
280. Hampton T. Scientists explore pathogenesis of IBD. JAMA. 2004;292:2708-2713.
281. Hugot JP, Laurent-Puig P, Gower-Rousseau C, et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature. 1996;379:821-823.
282. Gaya DR, Russell RK, Nimmo ER, Satsangi J. New genes in inflammatory bowel disease: lessons for complex diseases? Lancet. 2006;367:1271-1284.
283. Noble C, Nimmo E, Gaya D, Russell RK, Satsangi J. Novel susceptibility genes in inflammatory bowel disease. World J Gastroenterol. 2006;12:1991-1999.
284. Russell RK, Wilson DC, Satsangi J. Unravelling the complex genetics of inflammatory bowel disease. Arch Dis Child. 2004;89:598-603.
285. Russell RK, Drummond HE, Nimmo ER, et al. Analysis of the influence of OCTN1/2 variants within the IBD5 locus on disease susceptibility and growth indices in early onset inflammatory bowel disease. Gut. 2006;55:1114-1123.
286. Levine A, Shamir R, Wine E, et al. TNF promoter polymorphisms and modulation of growth retardation and disease severity in pediatric Crohn's disease. Am J Gastroenterol. 2005;100:1598-1604.
287. Lee JJ, Essers JB, Kugathasan S, et al. Association of linear growth impairment in pediatric Crohn's disease and a known height locus: a pilot study. Ann Hum Genet. 2010; 74:489-497.
288. Regan BP, Bousvaros A. Pediatric ulcerative colitis: a practical guide to management. Paediatr Drugs. 2014;16:189-198.
289. Stenke E, Hussey S. Ulcerative colitis: management in adults, children and young people (NICE Clinical Guideline CG166). Arch Dis Child Educ Pract Ed. 2014;99: 194-197.
290. Heuschkel R. Enteral nutrition should be used to induce remission in childhood Crohn's disease. Dig Dis. 2009;27: 297-305.
291. Sylvester FA. Effects of exclusive enteral nutrition on bone mass, linear growth and body composition in children with Crohn's disease. Nestle Nutr Inst Workshop Ser. 2014;79: 125-130.
292. HaismaSM, Lijftogt T, Kindermann A, et al. Methotrexate for maintaining remission in paediatric Crohn's patients with prior failure or intolerance to thiopurines: a multicenter cohort study. J Crohns Colitis. 2015;9:305-311.
293. Yang LS, Alex G, Catto-Smith AG. The use of biologic agents in pediatric inflammatory bowel disease. Curr Opin Pediatr. 2012;24:609-614.
294. Toussi SS, Pan N, Walters HM, Walsh TJ. Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature. Clin Infect Dis. 2013;57:1318-1330.
295. Mackey AC, Green L, Leptak C, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr. 2009;48:386-388.
296. Malik S, Wong SC, Bishop J, et al. Improvement in growth of children with Crohn disease following anti-TNF-α therapy can be independent of pubertal progress and glucocorticoid reduction. J Pediatr Gastroenterol Nutr. 2011; 52:31-37.
297. Malik S, Ahmed SF, Wilson ML, et al. The effects of anti-TNF-α treatment with adalimumab on growth in children with Crohn's disease (CD). J Crohns Colitis. 2012;6:337-344.
298. Church PC, Guan J, Walters TD, et al. Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease. Inflamm Bowel Dis. 2014;20:1177-1186.
299. Altowati MA, Russell RK, Ahmed SF. Endocrine therapy for growth retardation in paediatric inflammatory bowel disease. Paediatr Drugs. 2014;16:29-42.
300. Romano C, Famiani A, Gallizzi R, Comito D, Ferrau' V, Rossi P. Indeterminate colitis: a distinctive clinical pattern of inflammatory bowel disease in children. Pediatrics. 2008;122:e1278-e1281.
301. AhmedSF, Russell S, Rashid R, et al. Bone mineral content, corrected for height or bone area, measured byDXAis not reduced in children with chronic renal disease or in hypoparathyroidism. Pediatr Nephrol. 2005;20:1466-1472.
302. Abraham BP, Mehta S, El-Serag HB. Natural history of pediatric-onset inflammatory bowel disease: a systematic review. J Clin Gastroenterol. 2012;46:581-589.
303. Hildebrand H, Karlberg J, Kristiansson B. Longitudinal growth in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1994;18: 165-173.
304. Motil KJ, Grand RJ, Davis-Kraft L, Ferlic LL, Smith EO. Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology. 1993;105: 681-691.
305. Newby EA, Croft NM, Green M, et al. Natural history of paediatric inflammatory bowel diseases over a 5-year follow-up: a retrospective review of data from the register of paediatric inflammatory bowel diseases. J Pediatr Gastroenterol Nutr. 2008;46:539-545.
306. Pfefferkorn M, Burke G, Griffiths A, et al. Growth abnormalities persist in newly diagnosed children with Crohn disease despite current treatment paradigms. J Pediatr Gastroenterol Nutr. 2009;48:168-174.
307. Vasseur F, Gower-Rousseau C, Vernier-Massouille G, et al. Nutritional status and growth in pediatric Crohn's disease: a population-based study. AmJ Gastroenterol. 2010; 105:1893-1900.
308. Trauernicht AK, Steiner SJ. Serum antibodies and anthropometric data at diagnosis in pediatric Crohn's disease. Dig Dis Sci. 2012;57:1020-1025.
309. Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease. Gastroenterology. 1988;95:1523-1527.
310. DeBoer MD, Denson LA. Delays in puberty, growth, and accrual of bone mineral density in pediatric Crohn's disease: despite temporal changes in disease severity, the need for monitoring remains. J Pediatr. 2013;163:17-22.
311. Brain CE, Savage MO. Growth and puberty in chronic inflammatory bowel disease. Baillieres Clin Gastroenterol. 1994;8:83-100.
312. HoodHC, Cohen LE, Lee JJ. Late adolescent linear growth pattern in pediatric-onset inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2011;53:246-249.
313. Gupta N, Lustig RH, Kohn MA, VittinghoffE. Menarche in pediatric patients with Crohn's disease. Dig Dis Sci. 2012;57:2975-2981.
314. Ferguson A, Sedgwick DM. Juvenile onset inflammatory bowel disease: height and body mass index in adult life. BMJ. 1994;308:1259-1263.
315. Gupta N, Lustig RH, Kohn MA, McCracken M, VittinghoffE. Sex differences in statural growth impairment in Crohn's disease: role of IGF-1. Inflamm Bowel Dis. 2011; 17:2318-2325.
316. Castile RG, Telander RL, Cooney DR, et al. Crohn's disease in children: assessment of the progression of disease, growth, and prognosis. J Pediatr Surg. 1980;15:462-469.
317. Markowitz J, Grancher K, Rosa J, Aiges H, Daum F. Growth failure in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1993;16:373-380.
318. Alemzadeh N, Rekers-Mombarg LT, Mearin ML, Wit JM, Lamers CB, van Hogezand RA. Adult height in patients with early onset of Crohn's disease. Gut. 2002;51:26-29.
319. Lee JJ, Escher JC, Shuman MJ, et al. Final adult height of children with inflammatory bowel disease is predicted by parental height and patient minimum height Z-score. Inflamm Bowel Dis. 2010;16:1669-1677.
320. Herzog D, Buehr P, Koller R, et al. Gender differences in paediatric patients of the Swiss inflammatory bowel disease cohort study. Pediatr Gastroenterol Hepatol Nutr. 2014;17:147-154.
321. Thomas AG, Taylor F, Miller V. Dietary intake and nutritional treatment in childhood Crohn's disease. J Pediatr Gastroenterol Nutr. 1993;17:75-81.
322. Newby EA, Sawczenko A, Thomas AG, Wilson D. Interventions for growth failure in childhood Crohn's disease. Cochrane Database Syst Rev. 2005;3:CD003873.
323. Cameron FL, Gerasimidis K, Papangelou A, et al. Clinical progress in the two years following a course of exclusive enteral nutrition in 109 paediatric patients with Crohn's disease. Aliment Pharmacol Ther. 2013;37:622-629.
324. Wewer V, Riis L, Vind I, Husby S, Munkholm P, Paerregaard A. Infliximab dependency in a national cohort of children with Crohn's disease. J Pediatr Gastroenterol Nutr. 2006;42:40-45.
325. Sinitsky DM, Lemberg DA, Leach ST, Bohane TD, Jackson R, Day AS. Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease. J Gastroenterol Hepatol. 2010;25:810-816.
326. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology. 2000;119:895-902.
327. Navarro FA, Hanauer SB, Kirschner BS. Effect of longterm low-dose prednisone on height velocity and disease activity in pediatric and adolescent patients with Crohn disease. J Pediatr Gastroenterol Nutr. 2007;45:312-318.
328. Street ME, de'Angelis G, Camacho-Hübner C, et al. Relationships between serum IGF-1, IGFBP-2, interleukin-1β and interleukin-6 in inflammatory bowel disease. Horm Res. 2004;61:159-164.
329. Pasternak BA, D'Mello S, Jurickova II, et al. Lipopolysaccharide exposure is linked to activation of the acute phase response and growth failure in pediatric Crohn's disease and murine colitis. Inflamm Bowel Dis. 2010;16:856-869.
330. Tenore A, Berman WF, Parks JS, Bongiovanni AM. Basal and stimulated serum growth hormone concentrations in inflammatory bowel disease. J Clin Endocrinol Metab. 1977;44:622-628.
331. Kirschner BS, Sutton MM. Somatomedin-C levels in growth-impaired children and adolescents with chronic inflammatory bowel disease. Gastroenterology. 1986;91: 830-836.
332. Chong SK, Grossman A, Walker-Smith JA, Rees LH. Endocrine dysfunction in children with Crohn's disease. J Pediatr Gastroenterol Nutr. 1984;3:529-534.
333. Farthing MJ, Campbell CA, Walker-Smith J, Edwards CR, Rees LH, Dawson AM. Nocturnal growth hormone and gonadotrophin secretion in growth retarded children with Crohn's disease. Gut. 1981;22:933-938.
334. Grønbek H, Thøgersen T, Frystyk J, Vilstrup H, Flyvbjerg A, Dahlerup JF. Low free and total insulinlike growth factor I (IGF-I) and IGF binding protein-3 levels in chronic inflammatory bowel disease: partial normalization during prednisolone treatment. Am J Gastroenterol. 2002;97: 673-678.
335. Bannerjee K, Camacho-Hübner C, Babinska K, et al. Antiinflammatory and growth-stimulating effects precede nutritional restitution during enteral feeding in Crohn disease. J Pediatr Gastroenterol Nutr. 2004;38:270-275.
336. Beattie RM, Camacho-Hübner C, Wacharasindhu S, Cotterill AM, Walker-Smith JA, Savage MO. Responsiveness of IGF-I and IGFBP-3 to therapeutic intervention in children and adolescents with Crohn's disease. Clin Endocrinol (Oxf). 1998;49:483-489.
337. Eivindson M, Grønbaek H, Skogstrand K, et al. The insulin-like growth factor (IGF) system and its relation to infliximab treatment in adult patients with Crohn's disease. Scand J Gastroenterol. 2007;42:464-470.
338. Wong SC, Smyth A, McNeill E, et al. The growth hormone insulin-like growth factor 1 axis in children and adolescents with inflammatory bowel disease and growth retardation. Clin Endocrinol (Oxf). 2010;73:220-228.
339. Gupta N, Bostrom AG, Kirschner BS, et al. Gender differences in presentation and course of disease in pediatric patients with Crohn disease. Pediatrics. 2007;120:e1418-1425.
340. Kiepe D, Ulinski T, Powell DR, Durham SK, Mehls O, TönshoffB. Differential effects of insulin-like growth factor binding proteins-1,-2,-3, and-6 on cultured growth plate chondrocytes. Kidney Int. 2002;62:1591-1600.
341. Hoeflich A, Wu M, Mohan S, et al. Overexpression of insulin-like growth factor-binding protein-2 in transgenic mice reduces postnatal body weight gain. Endocrinology. 1999;140:5488-5496.
342. McCaffery TD Jr, Nasr K, Lawrence AM, Kirsner JB. Effect of administered human growth hormone on growth retardation in inflammatory bowel disease. Am J Dig Dis. 1974;19:411-416.
343. Henker J. Therapy with recombinant growth hormone in children with Crohn disease and growth failure. Eur J Pediatr. 1996;155:1066-1067.
344. Mauras N, George D, Evans J, et al. Growth hormone has anabolic effects in glucocorticosteroid-dependent children with inflammatory bowel disease: a pilot study. Metabolism. 2002;51:127-135.
345. WongSC, Hassan K, McGrogan P, Weaver LT, AhmedSF. The effects of recombinant human growth hormone on linear growth in children with Crohn's disease and short stature. J Pediatr Endocrinol Metab. 2007;20:1315-1324.
346. Heyman MB, Garnett EA, Wojcicki J, et al. Growth hormone treatment for growth failure in pediatric patients with Crohn's disease. J Pediatr. 2008;153:651-658, 658.e1-e3.
347. Slonim AE, Bulone L, Damore MB, Goldberg T, Wingertzahn MA, McKinley MJ. A preliminary study of growth hormone therapy for Crohn's disease. NEngl JMed. 2000; 342:1633-1637.
348. Slonim AE, Grovit M, Bulone L. Effect of exclusion diet with nutraceutical therapy in juvenile Crohn's disease. J Am Coll Nutr. 2009;28:277-285.
349. Calenda KA, Schornagel IL, Sadeghi-Nejad A, Grand RJ. Effect of recombinant growth hormone treatment on children with Crohn's disease and short stature: a pilot study. Inflamm Bowel Dis. 2005;11:435-441.
350. Denson LA, Kim MO, Bezold R, et al. A randomized controlled trial of growth hormone in active pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2010;51:130-139.
351. Wong SC, Kumar P, Galloway PJ, et al. A preliminary trial of the effect of recombinant human growth hormone on short-term linear growth and glucose homeostasis in children with Crohn's disease. Clin Endocrinol (Oxf). 2011; 74:599-607.
352. Wong SC, Dalzell AM, McGrogan P, Didi M, Laing P, Ahmed SF. The inflammatory milieu and the insulin like growth factor axis in children with inflammatory bowel disease following recombinant human growth hormone treatment. J Biol Regul Homeost Agents. 2015;29:27-37.
353. Kara E, Sungurtekin H, Sungurtekin U, Alkanat M, Ilkgul O. The effect of recombinant human growth hormone (rhGH) on trinitrobenzene sulfonic acid-induced colitis in rats: an experimental study. Inflamm Bowel Dis. 2004;10: 112-115.
354. Andiran N, Yordam N. TNF-α levels in children with growth hormone deficiency and the effect of long-term growth hormone replacement therapy. Growth Horm Igf Res. 2007;17:149-153.
355. Bozzola M, De Amici M, Zecca M, SchimpffRM, Rapaport R. Modulating effect of human growth hormone on tumour necrosis factor-α and interleukin-1β. Eur J Endocrinol. 1998;138:640-643.
356. Bozzola M, De Benedetti F, De Amici M, et al. Stimulating effect of growth hormone on cytokine release in children. Eur J Endocrinol. 2003;149:397-401.
357. Pagani S, Meazza C, Travaglino P, De Benedetti F, Tinelli C, Bozzola M. Serum cytokine levels in GH-deficient children during substitutive GH therapy. Eur J Endocrinol. 2005;152:207-210.
358. Pagani S, Meazza C, Travaglino P, Moretta A, Bozzola M. Effect of growth hormone therapy on the proinflammatory cytokine profile in growth hormone-deficient children. Eur Cytokine Netw. 2005;16:65-69.
359. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991;12:439-447.
360. Levy E, Gurbindo C, Lacaille F, Paradis K, Thibault L, Seidman E. Circulating tumor necrosis factor-α levels and lipid abnormalities in patients with cystic fibrosis. Pediatr Res. 1993;34:162-166.
361. Nixon LS, Yung B, Bell SC, Elborn JS, Shale DJ. Circulating immunoreactive interleukin-6 in cystic fibrosis. Am J Respir Crit Care Med. 1998;157:1764-1769.
362. Coutinho CA, Marson FA, Marcelino AR, et al. TNF-α polymorphisms as a potential modifier gene in the cystic fibrosis. Int J Mol Epidemiol Genet. 2014;5:87-99.
363. Shmarina G, Pukhalsky A, Petrova N, et al. TNF gene polymorphisms in cystic fibrosis patients: contribution to the disease progression. J Transl Med. 2013;11:19.
364. de Vries L, Griffiths A, Armstrong D, Robinson PJ. Cytokine gene polymorphisms and severity of CF lung disease. J Cyst Fibros. 2014;13:699-705.
365. Street ME, Ziveri MA, Spaggiari C, et al. Inflammation is a modulator of the insulin-like growth factor (IGF)/IGFbinding protein system inducing reduced bioactivity of IGFs in cystic fibrosis. Eur J Endocrinol. 2006;154:47-52.
366. Street ME, Spaggiari C, Volta C, et al. The IGF system and cytokine interactions and relationships with longitudinal growth in prepubertal patients with cystic fibrosis. Clin Endocrinol (Oxf). 2009;70:593-598.
367. Dhaliwal J, Leach S, Katz T, et al. Intestinal inflammation and impact on growth in children with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2015;60:521-526.
368. Walicka-Serzysko K, Sands D. The clinical presentations of pulmonary aspergillosis in children with cystic fibrosis-preliminary report. Dev Period Med. 2015;19:66-79.
369. Fillaux J, Brémont F, Murris M, et al. Aspergillus sensitization or carriage in cystic fibrosis patients. Pediatr Infect Dis J. 2014;33:680-686.
370. Mahdavinia M, Grammer LC. Management of allergic bronchopulmonary aspergillosis: a review and update. Ther Adv Respir Dis. 2012;6:173-187.
371. Lebecque P, Leonard A, De Boeck K, et al. Early referral to cystic fibrosis specialist centre impacts on respiratory outcome. J Cyst Fibros. 2009;8:26-30.
372. Woestenenk JW, Hoekstra T, Hesseling C, van der Doef HP, van der Ent CK. Comparison of height for age and height for bone age with and without adjustment for target height in pediatric patients with CF. J Cyst Fibros. 2011; 10:272-277.
373. Collins CE, MacDonald-Wicks L, Rowe S, O'Loughlin EV, Henry RL. Normal growth in cystic fibrosis associated with a specialised centre. Arch Dis Child. 1999;81:241-246.
374. Mahadeva R, Webb K, Westerbeek RC, et al. Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study. BMJ. 1998;316:1771-1775.
375. Lucidi V, Alghisi F, Raia V, et al. Growth assessment of paediatric patients with CF comparing different auxologic indicators: a multicentre Italian study. J Pediatr Gastroenterol Nutr. 2009;49:335-342.
376. Woestenenk JW, Stellato RK, Terheggen-Lagro SW, van der Ent CK, Houwen RH. The relationship between body growth and pulmonary function in children with cystic fibrosis. Acta Paediatr. 2014;103:162-167.
377. Zemel BS, Jawad AF, FitzSimmons S, Stallings VA. Longitudinal relationship among growth, nutritional status, and pulmonary function in children with cystic fibrosis: analysis of the Cystic Fibrosis Foundation National CF Patient Registry. J Pediatr. 2000;137:374-380.
378. Haeusler G, Frisch H, Waldhör T, Götz M. Perspectives of longitudinal growth in cystic fibrosis from birth to adult age. Eur J Pediatr. 1994;153:158-163.
379. Bournez M, Bellis G, Huet F. Growth during puberty in cystic fibrosis: a retrospective evaluation of a French cohort. Arch Dis Child. 2012;97:714-720.
380. Levy LD, Durie PR, Pencharz PB, Corey ML. Effects of long-term nutritional rehabilitation on body composition and clinical status in malnourished children and adolescents with cystic fibrosis. J Pediatr. 1985;107:225-230.
381. Shepherd RW, Holt TL, Thomas BJ, et al. Nutritional rehabilitation in cystic fibrosis: controlled studies of effects on nutritional growth retardation, body protein turnover, and course of pulmonary disease. J Pediatr. 1986;109: 788-794.
382. DalzellAM, ShepherdRW, DeanB, Cleghorn GJ, Holt TL, Francis PJ. Nutritional rehabilitation in cystic fibrosis: a 5 year follow-up study. J Pediatr Gastroenterol Nutr. 1992; 15:141-145.
383. Rosenfeld M, Casey S, Pepe M, Ramsey BW. Nutritional effects of long-term gastrostomy feedings in children with cystic fibrosis. J Am Diet Assoc. 1999;99:191-194.
384. HannaRM, Weiner DJ. Overweight and obesity in patients with cystic fibrosis: a center-based analysis. Pediatr Pulmonol. 2015;50:35-41.
385. Farrell PM, Kosorok MR, Rock MJ, et al. Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Pediatrics. 2001;107:1-13.
386. Pederzini F, D'Orazio C, Tamiazzo G, Faraguna D, Giglio L, Mastella G. Growth evaluation at one year of life in infants with cystic fibrosis diagnosed by neonatal screening. Pediatr Pulmonol Suppl. 1991;7:64-68.
387. Lai HC, Kosorok MR, Sondel SA, et al. Growth status in children with cystic fibrosis based on the National Cystic Fibrosis Patient Registry data: evaluation of various criteria used to identify malnutrition. J Pediatr. 1998;132:478-485.
388. Landon C, Rosenfeld RG. Short stature and pubertal delay in male adolescents with cystic fibrosis. Androgen treatment. Am J Dis Child. 1984;138:388-391.
389. Ghosal S, Taylor CJ, Pickering M, McGawJ. Head growth in cystic fibrosis following early diagnosis by neonatal screening. Arch Dis Child. 1996;75:191-193.
390. Ghosal S, Taylor CJ, PickeringM, McGawJ, Beckles-Willson N, Wales JK. Disproportionate head growth retardation in cystic fibrosis. Arch Dis Child. 1995;72:150-152.
391. Festini F, Taccetti G, Repetto T, et al. Gestational and neonatal characteristics of children with cystic fibrosis: a cohort study. J Pediatr. 2005;147:316-320.
392. Keller BM, Aebischer CC, Kraemer R, Schöni MH. Growth in prepubertal children with cystic fibrosis, homozygous for the Delta F508 mutation. J Cyst Fibros. 2003;2:76-83.
393. Bizzarri C, Montemitro E, Pedicelli S, et al. Glucose tolerance affects pubertal growth and final height of children with cystic fibrosis. Pediatr Pulmonol. 2015;50:144-149.
394. Vieni G, Faraci S, Collura M, et al. Stunting is an independent predictor of mortality in patients with cystic fibrosis. Clin Nutr. 2013;32:382-385.
395. Umlawska W, Sands D, Zielińska A. Age of menarche in girls with cystic fibrosis. Folia Histochemica Et Cytobiologica. 2010;48:185-190.
396. Johannesson M, Gottlieb C, Hjelte L. Delayed puberty in girls with cystic fibrosis despite good clinical status. Pediatrics. 1997;99:29-34.
397. Landon C, Rosenfeld RG. Short stature and pubertal delay in cystic fibrosis. Pediatrician. 1987;14:253-260.
398. Sinnema G, Van der Laag H, Stoop JW. Psychological development as related to puberty, body height and severity of illness in adolescents with cystic fibrosis. Israel J Med Sci. 1991;27:186-191.
399. Lai HC, Corey M, FitzSimmons S, Kosorok MR, Farrell PM. Comparison of growth status of patients with cystic fibrosis between the United States and Canada. Am J Clin Nutr. 1999;69:531-538.
400. Aswani N, Taylor CJ, McGaw J, Pickering M, Rigby AS. Pubertal growth and development in cystic fibrosis: a retrospective review. Acta Paediatr. 2003;92:1029-1032.
401. Assael BM, Casazza G, Iansa P, Volpi S, Milani S. Growth and long-term lung function in cystic fibrosis: a longitudinal study of patients diagnosed by neonatal screening. Pediatr Pulmonol. 2009;44:209-215.
402. Dijk FN, McKay K, Barzi F, Gaskin KJ, Fitzgerald DA. Improved survival in cystic fibrosis patients diagnosed by newborn screening compared to a historical cohort from the same centre. Arch Dis Child. 2011;96:1118-1123.
403. Morison S, Dodge JA, Cole TJ, et al. Height and weight in cystic fibrosis: a cross sectional study. UK Cystic Fibrosis Survey Management Committee. Arch Dis Child. 1997; 77:497-500.
404. Ciro D, Padoan R, Blau H, et al. Growth retardation and reduced growth hormone secretion in cystic fibrosis. Clinical observations from three CF centers. J Cyst Fibros. 2013;12:165-169.
405. Lebl J, Zahradníková M, Bartosová J, Zemková D, Pechová M, Vávrová V. Insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in cystic fibrosis: a positive effect of antibiotic therapy and hyperalimentation. Acta Paediatr. 2001;90:868-872.
406. OzenM, Cokugras H, OzenN, Camcioglu Y, Akcakaya N. Relation between serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 levels, clinical status, and growth parameters in prepubertal cystic fibrosis patients. Pediatr Int. 2004;46:429-435.
407. Laursen EM, Juul A, Lanng S, et al. Diminished concentrations of insulin-like growth factor I in cystic fibrosis. Arch Dis Child. 1995;72:494-497.
408. Switzer M, Rice J, Rice M, Hardin DS. Insulin-like growth factor-I levels predict weight, height and protein catabolism in children and adolescents with cystic fibrosis. J Pediatr Endocrinol Metab. 2009;22:417-424.
409. Sermet-Gaudelus I, Souberbielle JC, Azhar I, et al. Insulinlike growth factor I correlates with lean body mass in cystic fibrosis patients. Arch Dis Child. 2003;88:956-961.
410. Gifford AH, Nymon AB, Ashare A. Serum insulin-like growth factor-1 (IGF-1) during CF pulmonary exacerbation: trends and biomarker correlations. Pediatr Pulmonol. 2014;49:335-341.
411. Mason A, Wong SC, McGrogan P, Ahmed SF. Effect of testosterone therapy for delayed growth and puberty in boys with inflammatory bowel disease. Horm Res Paediatr. 2011;75:8-13.
412. Taylor AM, Thomson A, Bruce-Morgan C, et al. The relationship between insulin, IGF-I and weight gain in cystic fibrosis. Clin Endocrinol (Oxf). 1999;51:659-665.
413. Smerieri A, Montanini L, Maiuri L, Bernasconi S, Street ME. FOXO1 content is reduced in cystic fibrosis and increases with IGF-I treatment. Int J Mol Sci. 2014;15: 18000-18022.
414. Phung OJ, Coleman CI, Baker EL, et al. Recombinant human growth hormone in the treatment of patients with cystic fibrosis. Pediatrics. 2010;126:e1211-e1226.
415. Thaker V, Haagensen AL, Carter B, Fedorowicz Z, Houston BW. Recombinant growth hormone therapy for cystic fibrosis in children and young adults. Cochrane Database Syst Rev. 2013;6:CD008901.
416. Hardin DS, Ferkol T, Ahn C, et al. A retrospective study of growth hormone use in adolescents with cystic fibrosis. Clin Endocrinol (Oxf). 2005;62:560-566.
417. Hardin DS, Sy JP. Effects of growth hormone treatment in children with cystic fibrosis: The National Cooperative Growth Study experience. J Pediatr. 1997;131:S65-S69.
418. Hardin DS, Stratton R, Kramer JC, Reyes de la Rocha S, Govaerts K, Wilson DP. Growth hormone improves weight velocity and height velocity in prepubertal children with cystic fibrosis. Horm Metab Res. 1998;30:636-641.
419. Alemzadeh R, Upchurch L, McCarthy V. Anabolic effects of growth hormone treatment in young children with cystic fibrosis. J Am Coll Nutr. 1998;17:419-424.
420. Huseman CA, Colombo JL, Brooks MA, et al. Anabolic effect of biosynthetic growth hormone in cystic fibrosis patients. Pediatr Pulmonol. 1996;22:90-95.
421. Sackey AH, Taylor CJ, Barraclough M, Wales JK, Pickering M. Growth hormone as a nutritional adjunct in cystic fibrosis: results of a pilot study. J Hum Nutr Diet. 1995; 8:185-191.
422. Stalvey MS, Anbar RD, KonstanMW, et al. Amulti-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatr Pulmonol. 2012;47:252-263.
423. Hardin DS, Ellis KJ, Dyson M, Rice J, McConnell R, Seilheimer DK. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. J Pediatr. 2001;139:636-642.
424. Hardin DS, Adams-Huet B, Brown D, et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. J Clin Endocrinol Metab. 2006;91:4925-4929.
425. Schnabel D, Grasemann C, Staab D, Wollmann H, Ratjen F. A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics. 2007;119:e1230-e1238.
426. Hütler M, Schnabel D, Staab D, et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Med Sci Sports Exerc. 2002;34:567-572.
427. Hardin DS, Rice J, Ahn C, et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. J Pediatr. 2005;146: 324-328.
428. Bessich JL, Nymon AB, Moulton LA, Dorman D, Ashare A. Low levels of insulin-like growth factor-1 contribute to alveolar macrophage dysfunction in cystic fibrosis. J Immunol. 2013;191:378-385.
429. Lee HW, Cheng J, Kovbasnjuk O, Donowitz M, Guggino WB. Insulin-like growth factor 1 (IGF-1) enhances the protein expression of CFTR. PLoS One. 2013;8:e59992.
430. Schibler A, von der Heiden R, Birrer P, Mullis PE. Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Arch Dis Child. 2003; 88:1078-1081.
431. Gravholt CH, Naeraa RW, Brixen K, et al. Short-term growth hormone treatment in girls with Turner syndrome decreases fat mass and insulin sensitivity: a randomized, double-blind, placebo-controlled, crossover study. Pediatrics. 2002;110:889-896.
432. Sas TC, de Muinck Keizer-Schrama SM, Stijnen T, Aanstoot HJ, Drop SL. Carbohydrate metabolism during longterm growth hormone (GH) treatment and after discontinuation of GH treatment in girls with Turner syndrome participating in a randomized dose-response study. Dutch Advisory Group on Growth Hormone. J Clin Endocrinol Metab. 2000;85:769-775.
433. Colmenares A, Pinto G, Taupin P, et al. Effects on growth and metabolism of growth hormone treatment for 3 years in 36 children with Prader-Willi syndrome. Horm Res Paediatr. 2011;75:123-130.
434. Crinò A, Di Giorgio G, Manco M, Grugni G, Maggioni A. Effects of growth hormone therapy on glucose metabolism and insulin sensitivity indices in prepubertal children with Prader-Willi syndrome. Horm Res. 2007;68:83-90.
435. Lebl J, Lebenthal Y, Kolouskova S, et al. Metabolic impact of growth hormone treatment in short children born small for gestational age. Horm Res Paediatr. 2011;76:254-261.
436. Allen DB. Safety of growth hormone treatment of children with idiopathic short stature: the US experience. HormRes Paediatr. 2011;76(suppl 3):45-47.
437. Child CJ, Zimmermann AG, Scott RS, Cutler GB Jr, Battelino T, Blum WF. Prevalence and incidence of diabetes mellitus in GH-treated children and adolescents: analysis from the GeNeSIS observational research program. J Clin Endocrinol Metab. 2011;96:E1025-E1034.
438. Tsigos C, Papanicolaou DA, Kyrou I, Defensor R, Mitsiadis CS, Chrousos GP. Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab. 1997;82:4167-4170.
439. Horber FF, Marsh HM, Haymond MW. Differential effects of prednisone and growth hormone on fuel metabolism and insulin antagonism in humans. Diabetes. 1991; 40:141-149.
440. Bismuth E, Chevenne D, Czernichow P, Simon D. Moderate deterioration in glucose tolerance during high-dose growth hormone therapy in glucocorticoid-treated patients with juvenile idiopathic arthritis. Horm Res Paediatr. 2010;73:465-472.
441. Viner RM, White B, Barrett T, et al. Assessment of childhood obesity in secondary care: OSCA consensus statement. Arch Dis Child Educ Pract Ed. 2012;97:98-105.
442. O'Riordan SM, Hindmarsh P, Hill NR, et al. Validation of continuous glucose monitoring in children and adolescents with cystic fibrosis: a prospective cohort study. Diabetes Care. 2009;32:1020-1022.
443. Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab. 2010;95: 167-177.
444. Smida M, Nouri H, Kandara H, Jalel C, Ben Ghachem M. Bone diseases in children receiving growth hormone. Acta Orthop Belg. 2003;69:458-462.
445. Bowlby DA, Rapaport R. Safety and efficacy of growth hormone therapy in childhood. Pediatr Endocrinol Rev. 2004;2(suppl 1):68-77.
446. Fidler MW, Brook CG. Slipped upper femoral epiphysis following treatment with human growth hormone. J Bone Joint Surg Am. 1974;56:1719-1722.
447. Mostoufi-Moab S, IsaacoffEJ, Spiegel D, et al. Childhood cancer survivors exposed to total body irradiation are at significant risk for slipped capital femoral epiphysis during recombinant growth hormone therapy. Pediatr Blood Cancer. 2013;60:1766-1771.
448. Hussain WM, Hussain HM, Hussain MS, Ho SS. Human growth hormone and the development of osteochondritis dissecans lesions. Knee Surg Sports Traumatol Arthrosc. 2011;19:2108-2110.
449. Graham MF, Diegelmann RF, Elson CO, et al. Collagen content and types in the intestinal strictures of Crohn's disease. Gastroenterology. 1988;94:257-265.
450. Matthes H, Herbst H, Schuppan D, et al. Cellular localization of procollagen gene transcripts in inflammatory bowel diseases. Gastroenterology. 1992;102:431-442.
451. Fruchtman S, Simmons JG, Michaylira CZ, et al. Suppressor of cytokine signaling-2 modulates the fibrogenic actions ofGHand IGF-I in intestinal mesenchymal cells. AmJ Physiol Gastrointest Liver Physiol. 2005;289:G342-G350.
452. Theiss AL, Fuller CR, Simmons JG, Liu B, Sartor RB, Lund PK. Growth hormone reduces the severity of fibrosis associated with chronic intestinal inflammation. Gastroenterology. 2005;129:204-219.
453. Ergun-Longmire B, Mertens AC, Mitby P, et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab. 2006; 91:3494-3498.
454. Sklar CA, Mertens AC, Mitby P, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2002;87:3136-3141.
455. Mackenzie S, Craven T, Gattamaneni HR, Swindell R, Shalet SM, Brabant G. Long-term safety of growth hormone replacement after CNS irradiation. J Clin Endocrinol Metab. 2011;96:2756-2761.
456. Beukelman T, Haynes K, Curtis JR, et al. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012;64:1263-1271.
457. HorneffG, Foeldvari I, Minden K, Moebius D, Hospach T. Report on malignancies in the German juvenile idiopathic arthritis registry. Rheumatology. 2011;50:230-236.
458. Nordstrom BL, Mines D, Gu Y, Mercaldi C, Aquino P, Harrison MJ. Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents. Arthritis Care Res (Hoboken). 2012;64:1357-1364.
459. Herrinton LJ, Liu L, Levin TR, Allison JE, Lewis JD, Velayos F. Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology. 2012;143:382-389.
460. Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143: 390-399.e1.
461. Dagdelen S, Cinar N, Erbas T. Increased thyroid cancer risk in acromegaly. Pituitary. 2014;17:299-306.
462. Gullu BE, Celik O, Gazioglu N, Kadioglu P. Thyroid cancer is the most common cancer associated with acromegaly. Pituitary. 2010;13:242-248.
463. Rokkas T, Pistiolas D, Sechopoulos P, Margantinis G, Koukoulis G. Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis. World J Gastroenterol. 2008;14:3484-3489.
464. Steuerman R, Shevah O, Laron Z. Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies. Eur J Endocrinol. 2011;164: 485-489.
465. Melmed GY, Devlin SM, Vlotides G, et al. Anti-aging therapy with human growth hormone associated with metastatic colon cancer in a patient with Crohn's colitis. Clin Gastroenterol Hepatol. 2008;6:360-363.
466. Miller ME, Michaylira CZ, Simmons JG, et al. Suppressor of cytokine signaling-2: a growth hormone-inducible inhibitor of intestinal epithelial cell proliferation. Gastroenterology. 2004;127:570-581.
467. Michaylira CZ, Simmons JG, Ramocki NM, et al. Suppressor of cytokine signaling-2 limits intestinal growth and enterotrophic actions of IGF-I in vivo. Am J Physiol Gastrointest Liver Physiol. 2006;291:G472-G481.
468. Dobie R, MacRae VE, Huesa C, van't Hof R, Ahmed SF, Farquharson C. Direct stimulation of bone mass by increasedGHsignalling in the osteoblasts of Socs2-/-mice. J Endocrinol. 2014;223:93-106.
469. Savage MO, Blair JC, Jorge AJ, Street ME, Ranke MB, Camacho-Hübner C. IGFs and IGFBPs inGHinsensitivity. Endocr Dev. 2005;9:100-106.
470. Besson A, Salemi S, Eblé A, et al. PrimaryGHinsensitivity' (Laron syndrome) caused by a novel 4 kb deletion encompassing exon 5 of the GH receptor gene: effect of intermittent long-term treatment with recombinant human IGF-I. Eur J Endocrinol. 2004;150:635-642.
471. Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE. Long-term treatment with recombinant insulinlike growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab. 2007;92:902-910.
472. Backeljauw P, Bang P, Clayton PE, Geffner M, Woods KA. Diagnosis and management of primary insulin-like growth factor-I deficiency: current perspectives and clinical update. Pediatr Endocrinol Rev. 2010;7(suppl 1): 154-171.
473. Midyett LK, Rogol AD, Van Meter QL, Frane J, Bright GM. Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels: first-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2010;95:611-619.
474. Ranke MB. Treatment of children and adolescents with idiopathic short stature. Nat Rev Endocrinol. 2013;9: 325-334.
475. Vicari AP, Mocci S, Openshaw P, O'Garra A, Zlotnik A. Mouse γ δ TCR+NK1.1+ thymocytes specifically produce interleukin-4, are major histocompatibility complex class I independent, and are developmentally related toαβ TCR+NK1.1+ thymocytes. Eur J Immunol. 1996;26: 1424-1429.
476. Jensen RB, Thankamony A, O'Connell SM, et al. A randomised controlled trial evaluating IGF1 titration in contrast to currentGHdosing strategies in children born small for gestational age: the North European Smallfor-Gestational-Age Study. Eur J Endocrinol. 2014;171: 509-518.
477. Edmondson SR, Baker NL, Oh J, Kovacs G, Werther GA, Mehls O. Growth hormone receptor abundance in tibial growth plates of uremic rats: GH/IGF-I treatment. Kidney Int. 2000;58:62-70.